This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

WCLC 2017

IASLC 18th WORLD CONFERENCE ON LUNG CANCER

This event has ended

At WCLC 2017, Boehringer Ingelheim presented a symposium on treatment with afatinib*. Please find the agenda and downloadable slidesets below:

Symposium agenda

Maximising clinical benefit from TKIs in the treatment of advanced NSCLC

 1. Emerging Algorithm for optimal sequencing of EGFR TKIs in EGFR mutation-positive NSCLC | Keunchil Park

2. Effi­cacy of EGFR TKIs in NSCLC Patients With Uncommon EGFR mutations | Terufumi Kato

3. Considerations for choosing TKIs for squamous NSCLC in the era of immunotherapy: which patients could benefit? | Barbara Melosky

4. Panel Discussion: Carrying the data into the clinic: TKI sequencing decisions for EGFR mutation-positive NSCLC patients All

Download a copy of the agenda below:

Download the full slideset below:

Presentations

  • Monday 16 October 2017

    Poster presentation session

    • Mesothelioma

      LUME-Meso Phase II/III Study: Nintedanib + pemetrexed/cisplatin in chemo-naïve patients with malignant pleural mesothelioma. (Presentation #7937)

      Tsao et al.

  • Monday 16 October 2017

    Mini oral presentation session

    • Mesothelioma

      Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME‑Meso Study. (Presentation #8111)

      Nowak et al.

      This presentation was selected for inclusion in the European Thoracic Oncology Platform (ETOP) summary slide deck from WCLC 2017. 

  • Tuesday 17 October 2017

    Poster presentation session

    • Advanced NSCLC

      Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib. (Presentation #8797)

      Hochmair et al.

       

      Nintedanib/Docetaxel Efficacy in Advanced Lung Adenocarcinoma Treated with 1L Chemotherapy/2L Immunotherapy in Nintedanib NPU. (Presentation #8639)

      Corral et al.

  • Wednesday 18 October 2017

    Poster presentation session

    • Advanced NSCLC

      Sequential afatinib-osimertinib therapy in EGFR mutation-positive (EGFRm+) NSCLC: analysis of time on treatment and OS. (Presentation #9364)

      Park et al.

       

      Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC. (Presentation #9051)

      Schuler et al.

       

      A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis. (Presentation #9251)

      Wu et al.

       

      Afatinib dose adjustment: Effect on safety, efficacy and patient-reported outcomes in the LUX-Lung 3/6 trials in EGFRm+ NSCLC. (Presentation #9365)

      Hirsh et al.

       

      Post-marketing observational study of Japanese patients with EGFR mutation-positive (EGFRm+) NSCLC treated with daily afatinib (final report). (Presentation #8250)

      Yamamoto et al.

       

      Impact of ErbB mutations on clinical outcomes in afatinib- or erlotinib-treated patients with SCC of the lung. (Presentation #9457)

      Goss et al.

       

      Phase Ib trial of xentuzumab and abemaciclib in advanced or metastatic solid tumors, including advanced NSCLC. (Presentation #8572)

      Yee et al.

    • SqCC of the lung

      Afatinib in combination with pembrolizumab in patients with stage IIIB/IV squamous cell carcinoma of the lung. (Presentation #9425)

      Riess et al.

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

 

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.